FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer

Table 1 Patient characteristics n (%)

Characteristics	Irinotecan-naive cohort	Irinotecan-pre-exposed cohort	P-value
Age (yr)			0.793
< 70	21 (70.0)	23 (65.7)
≥ 70	9 (30.0)	12 (34.3)
Sex			0.623
Male	16 (53.3)	21 (60.0)
Female	14 (46.7)	14 (40.0)
ECOG PS			0.227
0	14 (46.7)	11 (31.4)
1	13 (43.3)	15 (42.9)
2	3 (10.0)	9 (25.7)
Time to metastasis			0.314
Metachronous	9 (30.0)	15 (42.9)
Synchronous	21 (70.0)	20 (57.1)
No. of metastatic sites			0.118
1	14 (46.7)	9 (25.7)
> 1	16 (53.3)	26 (74.3)
No. of prior lines for metastatic disease
			-
0	5 (16.7)	0 (0.0)
1	25 (83.3)	15 (42.9)
> 1	-	20 (57.1)
Prior drug exposure			0.699
Oxaliplatin	29 (96.7)	35 (100.0)
Bevacizumab	18 (60.0)	29 (82.9)
Anti-EGFR	2 (6.7)	4 (11.4)

ECOG PS: Eastern Cooperative Oncology Group performance status.